Literature DB >> 21658387

LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.

Etsuro Ohta1, Fumitaka Kawakami, Makoto Kubo, Fumiya Obata.   

Abstract

LRRK2 is the causal molecule for autosomal-dominant familial Parkinson's disease, although its true function, including its physiological substrates, remains unknown. Here, using in vitro kinase assay with recombinant proteins, we demonstrated for the first time that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction for cell survival and prevention of apoptosis. Ser473, one of two amino acids essential for Akt1 activation, was the target site for LRRK2. A knockdown experiment using intact cells also demonstrated LRRK2-mediated phosphorylation of Akt1 (Ser473), suggesting that Akt1 is a convincing candidate for the physiological substrate of LRRK2. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658387     DOI: 10.1016/j.febslet.2011.05.044

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson's Disease.

Authors:  William M Johnson; Marcin Golczak; Kyonghwan Choe; Pierce L Curran; Olga Gorelenkova Miller; Chen Yao; Wenzhang Wang; Jiusheng Lin; Nicole M Milkovic; Ajit Ray; Vijayalakshmi Ravindranath; Xiongwei Zhu; Mark A Wilson; Amy L Wilson-Delfosse; Shu G Chen; John J Mieyal
Journal:  Biochemistry       Date:  2016-08-01       Impact factor: 3.162

2.  Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.

Authors:  Kathrin Muda; Daniela Bertinetti; Frank Gesellchen; Jennifer Sarah Hermann; Felix von Zweydorf; Arie Geerlof; Anette Jacob; Marius Ueffing; Christian Johannes Gloeckner; Friedrich W Herberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

Review 3.  Leucine-rich repeat kinase 2 for beginners: six key questions.

Authors:  Lauren R Kett; William T Dauer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

4.  Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons.

Authors:  Salvatore J Cherra; Erin Steer; Aaron M Gusdon; Kirill Kiselyov; Charleen T Chu
Journal:  Am J Pathol       Date:  2012-12-08       Impact factor: 4.307

5.  Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.

Authors:  Keita Uchino; Fumitaka Takeshita; Ryou-U Takahashi; Nobuyoshi Kosaka; Kae Fujiwara; Haruna Naruoka; Satoru Sonoke; Junichi Yano; Hideo Sasaki; Shiari Nozawa; Miki Yoshiike; Kazuki Kitajima; Tatsuya Chikaraishi; Takahiro Ochiya
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

6.  Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Authors:  Liang Huang; Mika Shimoji; Juan Wang; Salim Shah; Sukanta Kamila; Edward R Biehl; Seung Lim; Allison Chang; Kathleen A Maguire-Zeiss; Xiaomin Su; Howard J Federoff
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 7.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

8.  LRRK2: dropping (kinase) inhibitions and seeking an (immune) response.

Authors:  Adamantios Mamais; Mark R Cookson
Journal:  J Neurochem       Date:  2014-03-24       Impact factor: 5.372

Review 9.  Parkinson's disease and cancer: two wars, one front.

Authors:  Michael J Devine; Hélène Plun-Favreau; Nicholas W Wood
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

10.  Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation.

Authors:  Lore Delbroek; Kristof Van Kolen; Liesbeth Steegmans; Raquel da Cunha; Wim Mandemakers; Guy Daneels; Pieter-Jan De Bock; Jinwei Zhang; Kris Gevaert; Bart De Strooper; Dario R Alessi; Patrik Verstreken; Diederik W Moechars
Journal:  J Pharm Biomed Anal       Date:  2012-12-16       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.